JP2008535909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535909A5 JP2008535909A5 JP2008506051A JP2008506051A JP2008535909A5 JP 2008535909 A5 JP2008535909 A5 JP 2008535909A5 JP 2008506051 A JP2008506051 A JP 2008506051A JP 2008506051 A JP2008506051 A JP 2008506051A JP 2008535909 A5 JP2008535909 A5 JP 2008535909A5
- Authority
- JP
- Japan
- Prior art keywords
- ccr2
- molecule
- mcp
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67147605P | 2005-04-15 | 2005-04-15 | |
| PCT/IL2006/000454 WO2006109301A2 (en) | 2005-04-15 | 2006-04-10 | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535909A JP2008535909A (ja) | 2008-09-04 |
| JP2008535909A5 true JP2008535909A5 (enExample) | 2009-04-02 |
Family
ID=36688002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506051A Pending JP2008535909A (ja) | 2005-04-15 | 2006-04-10 | Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8388962B2 (enExample) |
| EP (1) | EP1871798B1 (enExample) |
| JP (1) | JP2008535909A (enExample) |
| CN (1) | CN101160323A (enExample) |
| AT (1) | ATE445644T1 (enExample) |
| AU (1) | AU2006233927A1 (enExample) |
| CA (1) | CA2597789A1 (enExample) |
| DE (1) | DE602006009786D1 (enExample) |
| ES (1) | ES2333358T3 (enExample) |
| MX (1) | MX2007010484A (enExample) |
| WO (1) | WO2006109301A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007010484A (es) | 2005-04-15 | 2007-10-15 | Rappaport Family Inst For Res | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. |
| US20080118437A1 (en) * | 2006-03-01 | 2008-05-22 | Regents Of The University Of Michigan | Diagnosis and treatment O prostate cancer |
| WO2009028411A1 (ja) * | 2007-08-24 | 2009-03-05 | Keio University | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 |
| CN102370981B (zh) * | 2010-08-11 | 2014-07-16 | 中国科学院上海生命科学研究院 | 防治神经退行性疾病的试剂和方法 |
| WO2015020040A1 (ja) * | 2013-08-06 | 2015-02-12 | 国立大学法人九州大学 | 有機酸重合体を有効成分とする癌細胞の生着予防又は生着抑制のための医薬 |
| NO2776305T3 (enExample) * | 2014-04-23 | 2018-01-27 | ||
| CN107362353A (zh) * | 2016-05-11 | 2017-11-21 | 上海长海医院 | 一种去势抵抗的前列腺癌相关的药物靶点及其应用 |
| KR102308102B1 (ko) * | 2018-05-18 | 2021-10-07 | 가톨릭대학교 산학협력단 | Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물 |
| KR102308099B1 (ko) * | 2019-11-15 | 2021-10-01 | 가톨릭대학교 산학협력단 | Soluble CCR2 발현 유도된 줄기세포를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물 |
| WO2021095946A1 (ko) * | 2019-11-15 | 2021-05-20 | 가톨릭대학교 산학협력단 | Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0740701B1 (en) * | 1994-01-13 | 2006-12-06 | The Regents of the University of California | Mammalian monocyte chemoattractant protein receptors |
| SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
| US6528625B1 (en) | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
| CA2399593A1 (en) | 2000-02-09 | 2001-08-16 | Human Genome Sciences, Inc. | Antibodies to ccr5 |
| FR2828102B1 (fr) * | 2001-03-28 | 2004-07-09 | Ifc Sa | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| DE602004006871T2 (de) | 2003-07-24 | 2008-02-07 | Amgen Inc., Thousand Oaks | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
| IL157398A0 (en) | 2003-08-14 | 2004-02-19 | Hadasit Med Res Service | Pharmaceutical compositions comprising ccr5 antagonists |
| US7943130B2 (en) | 2003-12-11 | 2011-05-17 | Yale University | Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation |
| US20050215543A1 (en) | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
| MX2007010484A (es) | 2005-04-15 | 2007-10-15 | Rappaport Family Inst For Res | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. |
-
2006
- 2006-04-10 MX MX2007010484A patent/MX2007010484A/es active IP Right Grant
- 2006-04-10 WO PCT/IL2006/000454 patent/WO2006109301A2/en not_active Ceased
- 2006-04-10 AU AU2006233927A patent/AU2006233927A1/en not_active Abandoned
- 2006-04-10 CA CA002597789A patent/CA2597789A1/en not_active Abandoned
- 2006-04-10 DE DE602006009786T patent/DE602006009786D1/de active Active
- 2006-04-10 US US11/883,725 patent/US8388962B2/en not_active Expired - Fee Related
- 2006-04-10 EP EP06728255A patent/EP1871798B1/en not_active Not-in-force
- 2006-04-10 JP JP2008506051A patent/JP2008535909A/ja active Pending
- 2006-04-10 AT AT06728255T patent/ATE445644T1/de not_active IP Right Cessation
- 2006-04-10 ES ES06728255T patent/ES2333358T3/es active Active
- 2006-04-10 CN CNA2006800125405A patent/CN101160323A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535909A5 (enExample) | ||
| Foster et al. | Metastable supramolecular polymer nanoparticles via intramolecular collapse of single polymer chains | |
| Klok | Biological–synthetic hybrid block copolymers: combining the best from two worlds | |
| Lu et al. | N-trimethylsilyl amines for controlled ring-opening polymerization of amino acid N-carboxyanhydrides and facile end group functionalization of polypeptides | |
| Beck et al. | Facile preparation of nanoparticles by intramolecular cross-linking of isocyanate functionalized copolymers | |
| WO2007001422A3 (en) | High affinity antibodies against hmgb1 and methods of use thereof | |
| JP2023103456A5 (enExample) | ||
| WO2007084253A3 (en) | High affinity antibodies against hmgb1 and methods of use thereof | |
| Hoffman et al. | Really smart bioconjugates of smart polymers and receptor proteins | |
| Mahato | Biomaterials for delivery and targeting of proteins and nucleic acids | |
| JP2008538506A5 (enExample) | ||
| Yang et al. | Synthesis and characterization of polyrotaxanes consisting of cationic α-cyclodextrins threaded on poly [(ethylene oxide)-ran-(propylene oxide)] as gene carriers | |
| Frisch et al. | pH‐switchable self‐assembled materials | |
| Vandermeulen et al. | PEG-based hybrid block copolymers containing α-helical coiled coil peptide sequences: control of self-assembly and preliminary biological evaluation | |
| JP2010532997A5 (enExample) | ||
| JP2008523083A5 (enExample) | ||
| MX2007013031A (es) | Agentes terapeuticos de peptidos de toxina. | |
| JP2009527226A5 (enExample) | ||
| JP2010503630A5 (enExample) | ||
| JP2017500285A5 (enExample) | ||
| JP2008509227A5 (enExample) | ||
| JP2008539252A5 (enExample) | ||
| Ghosh et al. | Noncovalent template-assisted mimicry of multiloop protein surfaces: assembling discontinuous and functional domains | |
| JP2018535972A5 (enExample) | ||
| Tzokova et al. | The effect of PEO length on the self-assembly of poly (ethylene oxide)− tetrapeptide conjugates prepared by “click” chemistry |